Short- and long-term effect of high versus low-to-moderate intensity exercise to optimise health-related quality of life after oncological treatment—results from the Phys-Can project

Anna-Karin Ax1 · Birgitta Johansson2 · Johan Lyth1 · Karin Nordin3 · Sussanne Börjeson1

Received: 24 November 2021 / Accepted: 25 March 2022 / Published online: 7 April 2022 © The Author(s) 2022

Abstract

Purpose This study aimed to evaluate the effect of high intensity (HI) vs low-to-moderate intensity (LMI) exercise on health-related quality of life (HRQoL) up to 18 months after commencement of oncological treatment in patients with breast, colorectal or prostate cancer. In addition, we conducted a comparison with usual care (UC).

Methods Patients scheduled for (neo)adjuvant oncological treatment (n = 577) were randomly assigned to 6 months of combined resistance and endurance training of HI or LMI. A longitudinal descriptive study (UC) included participants (n = 89) immediately before the RCT started. HRQoL was assessed by EORTC QLQ-C30 at baseline, 3, 6 and 18 months (1 year after completed exercise intervention) follow-up. Linear mixed models were used to study the groups over time.

Results Directly after the intervention, HI scored significant (P = 0.02), but not clinically relevant, higher pain compared with LMI. No other significant difference in HRQoL was found between the exercise intensities over time. Clinically meaningful improvements in HRQoL over time were detected within both exercise intensities. We found favourable significant differences in HRQoL in both exercise intensities compared with UC over time.

Conclusion This study adds to the strong evidence of positive effect of exercise and shows that exercise, regardless of intensity, can have beneficial effects on HRQoL during oncological treatment and also for a substantial time after completion of an exercise intervention. In this study, for one year after.

Implications for cancer survivors Patients can be advised to exercise at either intensity level according to their personal preferences, and still benefit from both short-term and long-term improvements in HRQoL.

Keywords Cancer · Oncological treatment · Exercise · HRQoL

Introduction

The incidence of cancer is increasing worldwide, and fortunately more effective oncological treatments are resulting in improved survival [1]. The cancer disease and its treatment often have negative consequences, and compared with the general population, cancer survivors report a lower HRQoL (health-related quality of life) due to adverse outcomes both during treatment and in long-term survivorship [2–6]. A decline in HRQoL negatively affects functioning in daily life and hampers the transition to normal life [4]. Thus, it is important to promote interventions that can reduce or prevent adverse outcomes to enhance the HRQoL for the cancer survivors [7].

There is strong evidence that exercise has short-term beneficial effects on HRQoL and can improve or prevent a decline in physical, emotional, and role functioning and can
reduce symptoms while the oncological treatment is ongoing [8–15]. A meta-analysis showed that exercise during, and especially in the months after oncological treatment, had small favourable effects on fatigue and physical functioning compared to usual care up to six-month follow-up [16]; however, long-term effects of exercise on HRQoL are unclear. Combined endurance and resistance training two to three times per week for at least 12 weeks is recommended to improve HRQoL during and after treatment [6, 15]. However, there is insufficient evidence regarding what level of exercise intensity is required to optimise HRQoL most in the short and longer terms. To our knowledge, no study has compared combined endurance and resistance training of high intensity vs. low intensity during oncological treatment or examined the effects on HRQoL up to 1 year after completion of an exercise intervention. A previous RCT compared a supervised exercise programme with combined endurance and resistance training of moderate-to-high intensity, with a home-based walking programme of low intensity. Fewer symptoms of obstipation were found in the moderate-to-high intensity group compared with the low intensity group directly after the exercise intervention; however, no differences were found at the 6 months follow-up. [17]. Another RCT compared combined supervised endurance and resistance training of high intensity vs. low intensity after chemotherapy treatment [18, 19]. They found no differences between the different exercise intensities on HRQoL directly after the intervention [18] but did find larger effects of high intensity exercise for social and role functioning compared with low intensity exercise at the one year follow-up after the intervention [19]. Thus, larger randomised studies with a longer follow-up are warranted to further improve the optimal exercise prescription regarding exercise intensity during treatment and to study whether improvements in HRQoL persist over time.

Recently, the short-term main results of the randomised controlled trial Physical Training and Cancer (Phys-Can), determining the effects of a 6-month combined endurance and resistance training programme of (high intensity) HI vs (low-to-moderate intensity) LMI exercise in patients undergoing (neo-)adjuvant treatment, was published [20]. Directly after the intervention was completed, HI exercise yielded statistically significant reduced physical fatigue (the primary outcome) and improved muscle strength and cardiorespiratory fitness compared with LMI exercise. However, there were no other differences between the exercise intensities in overall HRQoL, anxiety, depression, functioning in daily life or sleep. The present study reports the HRQoL in more detail up to 1 year after completion of the exercise intervention in Phys-Can. Hence, this study aimed to evaluate the effect of HI vs LMI exercise on HRQoL up to 18 months after commencement of oncological treatment (12 months after the end of the intervention) in patients with breast, colorectal or prostate cancer. In addition, we conducted a comparison with usual care (UC).

Patients and method

Research design and study sample

This is a study on secondary outcomes from the Phys-Can project. The Phys-Can project is a non-blinded RCT (NCT02473003, www.clinicaltrials.gov), with a preceding longitudinal descriptive study with UC to be used as comparison (hereinafter referred as UC). The design of the Phys-Can project is described in detail elsewhere [21]. For the RCT, a 2×2 factorial design was used, comparing LMI vs HI exercise with or without additional self-regulatory behaviour change strategies (BCS), for 6 months during oncological treatment. BCS focused on strategies for adherence to the endurance training [21]. However, additional BCS was not beneficial for any of the study outcomes, nor for overall HRQoL directly after the intervention [20]. In the present study, we focused on differences between exercise intensities.

Participants were consecutively recruited at three university hospitals in Sweden from September 2014 to March 2015 (UC) and March 2015 to May 2018 (RCT) (Fig. 1). Participants were eligible if diagnosed with breast, colorectal or prostate cancer and scheduled for (neo)adjuvant oncological treatment. Exclusion criteria were inability to perform basic activities of daily living, cognitive disorders, severe emotional instability, or other conditions for which physical exercise is contradicted. The sample size calculation in the RCT was based on the primary outcome of cancer-related fatigue (assessed with the Multidimensional Fatigue Inventory [22]) [21]. The study was approved by the Swedish Ethical Review Authority in Uppsala (Dnr 2014/249). Written informed consent was obtained from all participants.

Procedure

Baseline measurements were collected before oncological treatment in both the UC and the RCT. Then participants in the RCT were randomly assigned to HI, HI + BCS, LMI, or LMI + BCS (Fig. 1). The randomisation was computer-generated with a random allocation sequence (1:1:1:1) and carried out with eight patients per block within each stratum (three hospitals and three diagnoses).

Intervention

The exercise programme consisted of endurance training and resistance training for 6 months and was initiated
when the oncological treatment started, as described in detail elsewhere [20, 21]. For endurance training (home-based), participants in HI performed interval sessions twice a week, alternating between 2 min of exercise (e.g. running) at an exercise intensity of 80–90% of the heart rate reserve (HRR) with 2 min of active rest (e.g. walking). Participants started with 5 intervals and were adding intervals up to a maximum of 10 intervals. In LMI, participants performed at least 150 min per week (i.e. walking and bicycling) at an exercise intensity of 40–50% of the HRR in bouts of at least 10 min. HRR was determined from VO2max test performed at baseline. Heart rate monitors were used for monitoring of
exercise intensity. The resistance training was supervised and performed twice a week in groups in a public gym. The HI group performed 6 repetitions maximum (RM) × 3 sets (first weekly session) and 10 RM × 3 sets (second weekly session). The LMI group performed 12 repetitions (50% of 6 RM) × 3 sets (first weekly session) and 10 repetitions (50% of 10 RM) × 3 sets (second weekly session). The progression was based on testing of 6 and 10 RM every 4–6 weeks. The resistance training was performed on machines: seated leg press, chest press, leg extension, seated row, seated leg curl and seated overhead press using dumbbells. In addition, core exercises were performed. Participants were closely monitored. The coaches checked for intensity and overall adherence to the exercise protocol and gave feedback on the exercise being performed. Adverse events during exercise were assessed by both coaches and participants and revealed mainly minor musculoskeletal injuries and/or discomfort [23].

**Timing of assessments and study measures**

Follow-up data collection was completed in November 2019. Participants completed the HRQoL questionnaire at baseline, after 3 months (mid-intervention for the RCT), after 6 months (end of the intervention for the RCT) and after 18 months (1 year after the end of the intervention for the RCT). Medical background data were collected from the medical records and the Swedish National Quality Registers. Socio-demographic data were self-reported (study-specific questions). HRQoL was assessed by The European Organisation for Research and Treatment of Cancer, Quality of Life Questionnaire C30 (EORTC QLQ-C30) [24, 25], which is a questionnaire validated for the cancer population, and consists of a 30-item questionnaire, covering a global health status/quality of life (QoL) scale, five functioning scales, three symptom scales and six items concerning symptoms. All scales and single-item measures were transformed to scores in the range 0–100. A higher score on the global status scale and the functional scales denotes a high level of health and functioning, while a higher score on the symptomatic scale denotes a high level of symptom burden [26]. In addition, participants with breast cancer completed EORTC QLQ-BR23 [27], participants with colorectal cancer completed EORTC QLQ-CR29 [28] and participants with prostate cancer completed EORTC QLQ-PR25 [29].

**Statistical analysis**

Analysis was conducted as intention-to-treat and carried out using IBM statistics SPSS 25. Descriptive analysis was used to present background characteristics and the scores of the HRQoL outcome. To compare background characteristics between the groups, a Chi2-test was used for categorical data and ANOVA for continuous data. Linear mixed models were used to estimate the longitudinal changes of each HRQoL variable. A normal distribution assumption was made for all HRQoL variables used in the linear mixed models, but robust covariances were used to allow violations of the model assumption. Time was considered categorical, and in all models, an interaction term between time and group was included. The baseline measurement of each outcome and age, education, hospital, cancer diagnosis and chemotherapy (Yes/No) were included as potential confounders or auxiliary variables. Estimated marginal means were calculated from the models, and contrasts were used to calculate all adjusted pairwise p values between groups for each measurement. We did not correct for multiplicity, given the exploratory nature of the study. To illustrate the percentage change between groups (Fig. 2), estimated marginal means and corresponding 95% confidence intervals (CI) were rescaled by dividing all values in each group by the baseline value for that group. P values < 0.05 were considered statistically significant. To estimate clinically meaningful changes over time, we used guidelines with thresholds for deterioration/improvements in points of each scale of HRQoL, as trivial, small, medium or large [30]. To estimate clinically relevant differences between groups, we used guidelines with thresholds of mean difference in points of each scale of HRQoL, as trivial, small, medium or large [31]. Logistic regression analysis was conducted to identify possible factors associated with dropouts (age, diagnosis, hospital, treatment, educational level, life situation and comorbidities).

**Results**

Overall, 577 participants were randomly assigned to HI (n = 288) and LMI (n = 289) in the RCT, and 89 participants were included in the UC study. Socio-demographic and medical background characteristics were well balanced across groups, except that a lower proportion of participants with breast cancer received chemotherapy in UC (P < 0.01) compared with the RCT. The mean age was 58 years (22–85 years); 539 (81%) were female; 530 (80%) had breast cancer; 109 (16%) had prostate cancer and 27 (4%) had colorectal cancer (Table 1). Baseline questionnaires were completed for 97% (HI), 98% (LMI) and 99% (UC). The response rate was > 71% for all measurements. Participants in the UC study were more likely to drop out compared with the RCT, HI (OR: 0.46, 95% CI, 0.27–0.81, P < 0.01) and LMI: (OR: 0.32, 95% CI, 0.18–0.57, P < 0.01). From baseline to 18 months, there was a 28% drop-out from UC, 18% from HI and 16% from LMI (Fig. 1). There were no systematic non-answers to any HRQoL item.
HRQoL

**High intensity and low-to-moderate intensity**

At 6 months, we found statistically significant higher pain in participants randomised to HI exercise compared to LMI exercise; however, this difference was not clinically relevant (Table 2). The most prominent clinically meaningful changes over time within both exercise intensities were improved global health status/QoL, reduced symptoms of appetite loss, and improved social, emotional, and role functioning (Table 2). When exploring each group over time, from the time period when the intervention was completed until 1 year after, significant changes within each group were only found for cognitive functioning (HI: 95% CI, −4.9 to −0.3 and LMI: 95% CI −4.9 to −0.5), which improved in both exercise intensities. This indicated that the exercise-induced improvements at the end of the intervention persisted in the longer term.

**High intensity, low-to-moderate intensity and usual care**

Additionally, we compared the exercise intensities with UC and found statistically significant differences in favour of the exercise groups compared with UC. At 3 months, both the HI and LMI groups reported better global health status/
QoL (mean difference = 5.5; 95% CI, 0–11 and mean difference = 6.9; 95% CI, 1.5–12, respectively), and the LMI group reported better emotional functioning (mean difference = 4.9; 95% CI, 0.4–9.4). At 6 months, both the HI and LMI groups reported better global health status/QoL, physical- and role functioning. Both the HI and LMI groups reported less fatigue, and the HI group reported less dyspnoea (Table 2). At 18 months, both the HI and LMI groups reported better emotional functioning. The LMI group reported better global health status/QoL and less fatigue (Table 2). The significant changes over time are presented in Fig. 2.

### Diagnosis-specific HRQoL

#### High intensity and low-to-moderate intensity

No statistically significant differences were observed between the exercise intensities over time.

#### High intensity, low-to-moderate intensity, and usual care

Statistically significant differences were observed at the 3-month measurement between the exercise intensities and UC. In participants with breast cancer, both the HI and

---

**Table 1** Medical background characteristics of high- and low-to-moderate intensity exercise and usual care in patients undergoing (neo)adjuvant oncological treatment

| Medical Background Characteristics | HI (n = 288) | LMI (n = 289) | UC (n = 89) | P (between groups) |
|-----------------------------------|-------------|--------------|-------------|--------------------|
| Age (years), mean (SD)            |             |              |             | 0.997\(^1\)        |
| Sex, n (%)                        |             |              |             | 0.827\(^2\)        |
| Male                              |             |              |             |                    |
| Female                            |             |              |             |                    |
| Number of comorbidities           |             |              |             | 0.624\(^2\)        |
| 0                                 | 113 (42)    | 109 (39)     | 37 (45)     |                    |
| 1                                 | 84 (31)     | 88 (31)      | 29 (35)     |                    |
| 2                                 | 46 (17)     | 58 (21)      | 11 (13)     |                    |
| 3+                                | 27 (10)     | 24 (8.6)     | 5 (6.1)     |                    |
| Breast cancer                     | 228         | 229          | 73          |                    |
| Stage I (T1N0M0) and in situ      | 122 (61)    | 113 (56)     | 39 (66)     | 0.301\(^2,3\)      |
| Stage II (T1-2N1M0, T2-3N0M0)     | 74 (37)     | 79 (39)      | 20 (34)     |                    |
| Stage III (T1-2N2M0, T3N1-2M0)    | 5 (2.5)     | 11 (5.4)     | 0 (0)       |                    |
| Chemotherapy/target therapy total | 118 (65)    | 127 (66)     | 24 (41)     | 0.002\(^2\)        |
| Anthracycline and/or Taxane       | 84 (71)     | 91 (78)      | 19 (79)     |                    |
| Anthracycline and/or Taxane + target therapy + antibody | 34 (29) | 36 (29) | 5 (21) | |
| Radiotherapy                      | 170 (81)    | 177 (84)     | 44 (75)     | 0.261\(^2\)        |
| Endocrine therapy                 | 147 (70)    | 164 (77)     | 48 (79)     | 0.135\(^2\)        |
| Prostate cancer                   | 49          | 48           | 12          |                    |
| TNM classification                |             |              |             |                    |
| T1a-cN0M0                         | 23 (50)     | 18 (41)      | 7 (64)      | 0.649\(^2\)        |
| T2N0M0                            | 16 (35)     | 17 (39)      | 2 (18)      |                    |
| T3-4N0M0, T1c-4N1M0               | 7 (15)      | 9 (21)       | 2 (18)      |                    |
| Radio- and/or brachy therapy      | 44 (100)    | 45 (100)     | 11 (100)    | -                  |
| Endocrine therapy                 | 25 (57)     | 25 (53)      | 7 (64)      | 0.810\(^2\)        |
| Colorectal cancer                 | 11          | 12           | 4           |                    |
| Stage II (T3-4N0M0)               | 2 (20)      | 3 (27)       | 1 (25)      |                    |
| Stage III (T3-4N1-2M0, T3N1M1)    | 8 (80)      | 8 (73)       | 3 (75)      |                    |
| Chemotherapy                      |             |              |             |                    |
| Oxaliplatin and/or Capecitabine   | 9 (100)     | 11 (100)     | 4 (100)     | 4                   |

HI = high intensity exercise; LMI = low-to-moderate intensity exercise, UC = usual care. TNM classification according to AJCC, 2017. T: tumour size. N: lymph node status. 1. One-way ANOVA analysis, Bonferroni post-hoc test. 2. Chi-2-test. 3. Stage II and III were merged in the analysis. 4. Too few numbers to perform analysis.
### Table 2: Longitudinal crude mean scores and estimated clinically relevant differences between groups and meaningful changes within groups of EORTC QLQ-C30, of high- and low-to-moderate intensity exercise and usual care

| Maximum number of respondents | Baseline | 3 months | 6 months | 18 months | Between groups differences at 6 months (95% CI and $P$) | Clinically meaningful changes within groups from baseline to 6 months$^a$ | Between groups differences at 18 months (95% CI and $P$) | Clinically meaningful changes within groups from baseline to 18 months$^a$ | Clinically meaningful changes within group from baseline to 18 months$^a$ |
|-----------------------------|----------|----------|----------|-----------|------------------------------------------------------|-------------------------------------------------|-------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|
| **HI**                     | 279      | 210      | 220      | 208       |                                                      | +7 Small*                                         | -2.3 (-5.7 to 1.1) | 0.18 -2 Trivial                                         | +6 Small*                                              |
| **LMI**                    | 283      | 206      | 229      | 214       |                                                      | +9 Medium*                                         | 4.8 (-0.8 to 10)  | 0.09 +5 Small                                          | +9 Medium*                                              |
| **UC**                     | 88       | 56       | 56       | 49        |                                                      |                                                  |                                                  |                                                        |                                                        |
| **Global health status**   |          |          |          |           |                                                      |                                                  |                                                  |                                                        |                                                        |
| **HI**                     | 67 (20)  | 64 (23)  | 75 (19)  | 74 (19)   | -0.6 (-3.6 to 2.4) 0.70 -1 Trivial                   | +10 Medium*                                       | 7.1 (1.7 to 13)  | 0.01 +7 Small*                                         | +1 Trivial                                              |
| **LMI**                    | 65 (20)  | 65 (22)  | 74 (19)  | 74 (18)   | 10 (5.1–16) <0.01 +11 Medium*                         |                                                  |                                                  |                                                        |                                                        |
| **UC**                     | 69 (19)  | 64 (20)  | 67 (21)  | 74 (18)   | 10 (5.8–16) <0.01 +11 Medium*                         |                                                  |                                                  |                                                        |                                                        |
| **HI vs LMI**              |          |          |          |           |                                                      |                                                  |                                                  |                                                        |                                                        |
| **HI vs UC**               | 10 (5.1–16) | <0.01 | +1 Trivial | 3 Trivial | 2 Trivial | +10 Medium* | 4.8 (-0.8 to 10) | 0.09 +5 Small | +1 Trivial |                                                        |
| **LMI vs UC**              | 10 (5.8–16) | <0.01 | +1 Trivial | 3 Trivial | 2 Trivial | +10 Medium* | 7.1 (1.7 to 13) | 0.01 +7 Small | +1 Trivial |                                                        |
| **Functioning**            |          |          |          |           |                                                      |                                                  |                                                  |                                                        |                                                        |
| **Physical functioning**   |          |          |          |           |                                                      |                                                  |                                                  |                                                        |                                                        |
| **HI**                     | 89 (13)  | 85 (16)  | 90 (13)  | 80 (14)   | 0 (-2.0 to 2.0) 0.99 0 Trivial                        | +1 Trivial                                        | -1.0 (-3.4 to 1.3) | 0.38 +1 Trivial                                         | +1 Trivial                                              |
| **LMI**                    | 88 (14)  | 85 (15)  | 90 (12)  | 89 (14)   | 4.4 (0.5 to 8.3) 0.03 +4 Trivial*                     | +1 Trivial                                        | 0.4 (-3.9 to 4.7) | 0.86 0 Trivial                                         | +1 Trivial                                              |
| **UC**                     | 90 (11)  | 88 (11)  | 88 (14)  | 90 (13)   | 4.4 (0.5 to 8.3) 0.03 +4 Trivial*                     | +1 Trivial                                        | 1.4 (-2.9 to 5.7) | 0.51 +1 Trivial                                         | +1 Trivial                                              |
| **HI vs LMI**              |          |          |          |           |                                                      |                                                  |                                                  |                                                        |                                                        |
| **HI vs UC**               | 4.4 (0.5 to 8.3) | 0.03 | +4 Trivial* | 0 Trivial | 3 Trivial | +10 Medium* | 1.4 (-2.9 to 5.7) | 0.51 +1 Trivial | +1 Trivial |                                                        |
| **LMI vs UC**              | 4.4 (0.5 to 8.3) | 0.03 | +4 Trivial* | 0 Trivial | 3 Trivial | +10 Medium* | 7.1 (1.7 to 13) | 0.01 +7 Small | +1 Trivial |                                                        |
| **Role functioning**       |          |          |          |           |                                                      |                                                  |                                                  |                                                        |                                                        |
| **HI**                     | 74 (23)  | 70 (32)  | 83 (24)  | 84 (25)   | -2.8 (-6.7 to 1.3) 0.18 -3 Trivial                    | +9 Small*                                         | -1.2 (-5.9 to 3.5) | 0.62 -1 Trivial                                         | +10 Small*                                              |
| **LMI**                    | 73 (29)  | 72 (30)  | 86 (21)  | 85 (23)   | 8.5 (1.5 to 16) 0.02 +9 Small*                        | +12 Small*                                        | -0.1 (-7.1 to 6.9) | 0.98 0 Trivial                                         | +11 Small*                                              |
| **UC**                     | 77 (27)  | 73 (30)  | 80 (24)  | 90 (19)   | 8.5 (1.5 to 16) 0.02 +9 Small*                        | 0 Trivial                                         | 1.2 (-6.1 to 8.2) | 0.77 +1 Trivial                                         |                                                        |
| **HI vs LMI**              |          |          |          |           |                                                      |                                                  |                                                  |                                                        |                                                        |
| **HI vs UC**               | -2.8 (-6.7 to 1.3) | 0.18 | -3 Trivial | 0 Trivial | 3 Trivial | +10 Medium* | -1.2 (-5.9 to 3.5) | 0.62 -1 Trivial | +10 Small*                                              |
| **LMI vs UC**              | 8.5 (1.5 to 16) | 0.02 | +9 Small* | 0 Trivial | 3 Trivial | +10 Medium* | 1.2 (-6.1 to 8.2) | 0.77 +1 Trivial |                                                        |
Table 2 (continued)

|                      | Baseline | 3 months | 6 months | 18 months | Between groups differences at 6 months (95% CI and P) | Clinically meaningful changes within group from baseline to 6 months<sup>a</sup> | Between groups differences at 18 months (95% CI and P) | Clinically relevant differences between groups at 18 months<sup>b</sup> | Clinically meaningful changes within group from baseline to 18 months<sup>b</sup> |
|----------------------|----------|----------|----------|-----------|-----------------------------------------------------|--------------------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------------|------------------------------------------------------------------------|
| Emotional functioning |          |          |          |           |                                                     |                                                                                  |                                                                  |                                                                        |                                                                        |
| HI                   | 72 (22)  | 77 (21)  | 79 (22)  | 81 (20)   | + 7 Small*                                          |                                                                                  |                                                                  |                                                                        |                                                                        |
| LMI                  | 71 (21)  | 78 (21)  | 80 (19)  | 82 (17)   | + 8 Small*                                          |                                                                                  |                                                                  |                                                                        |                                                                        |
| UC                   | 75 (21)  | 77 (23)  | 82 (20)  | 79 (19)   | + 5 Trivial*                                        |                                                                                  |                                                                  |                                                                        |                                                                        |
| HI vs LMI            |          |          |          |           | -1.0 (-3.9 to 1.9)                                 | 0.50 -1 NA                                                                     | 0.5 (-3.6 to 2.6)                                                 | 0.74 -1 NA                                                            | + 1 Trivial                                                            |
| HI vs UC             |          |          |          |           | 0.5 (-4.9 to 5.9)                                  | 0.86 + 1 NA                                                                   | 6.9 (1.2 to 12.6)                                               | 0.02 + 7 NA                                                          | + 1 Trivial                                                            |
| LMI vs UC            |          |          |          |           | 1.5 (-3.7 to 6.7)                                  | 0.57 + 1 NA                                                                   | 7.5 (1.9 to 13.0)                                               | 0.01 + 7 NA                                                          |                                                                        |
| Cognitive functioning |          |          |          |           |                                                     |                                                                                  |                                                                  |                                                                        |                                                                        |
| HI                   | 82.4 (20.4) | 78 (23) | 83 (21)  | 85 (18)   | + 2 Trivial                                        |                                                                                  |                                                                  |                                                                        |                                                                        |
| LMI                  | 82 (21)  | 78 (23)  | 81 (19)  | 84 (17)   | -1 Trivial                                         |                                                                                  |                                                                  |                                                                        |                                                                        |
| UC                   | 84 (21)  | 83 (20)  | 83 (19)  | 86 (18)   | -1 Trivial                                         |                                                                                  |                                                                  |                                                                        |                                                                        |
| HI vs LMI            |          |          |          |           | 0.6 (-2.4 to 3.7)                                  | 0.68 + 1 Trivial                                                               | 0.6 (-2.5 to 3.7)                                               | 0.72 + 1 Trivial                                                     |                                                                        |
| HI vs UC             |          |          |          |           | 1.2 (-4.8 to 7.2)                                  | 0.70 + 1 Trivial                                                               | 3.1 (-1.5 to 7.7)                                               | 0.19 + 3 Trivial                                                     |                                                                        |
| LMI vs UC            |          |          |          |           | 0.5 (5.4 to 6.5)                                  | 0.86 + 1 Trivial                                                               | 2.5 (-2.0 to 7.1)                                               | 0.28 + 3 Trivial                                                     |                                                                        |
| Social functioning    |          |          |          |           |                                                     |                                                                                  |                                                                  |                                                                        |                                                                        |
| HI                   | 81 (22)  | 75 (25)  | 83 (21)  | 85 (22)   | + 2 Trivial                                        |                                                                                  |                                                                  |                                                                        |                                                                        |
| LMI                  | 78 (23)  | 73 (25)  | 84 (20)  | 85 (20)   | + 5 Small*                                         |                                                                                  |                                                                  |                                                                        |                                                                        |
| UC                   | 83 (21)  | 77 (25)  | 82 (24)  | 87 (20)   | + 3 Trivial                                        |                                                                                  |                                                                  |                                                                        |                                                                        |
| HI vs LMI            |          |          |          |           | -2.3 (-5.7 to 1.0)                                 | 0.17 -2 Trivial                                                               | -2.2 (-6.1 to 1.6)                                              | 0.26 -2 Trivial                                                      |                                                                        |
| HI vs UC             |          |          |          |           | 3.4 (-3.3 to 10)                                  | 0.32 3 Trivial                                                                | 1.6 (-5.2 to 8.3)                                               | 0.65 2 Trivial                                                      |                                                                        |
| LMI vs UC            |          |          |          |           | 5.7 (-1.0 to 12)                                  | 0.09 + 6 Small                                                               | 3.8 (-3.0 to 11)                                               | 0.27 + 4 Trivial                                                     |                                                                        |
Table 2 (continued)

|            | Mean (SD) | Baseline  | 3 months | 6 months | 18 months | Between groups differences at 6 months (95% CI and $P$) | Clinically relevant differences between groups at 6 months$^a$ | Between groups differences at 18 months (95% CI and $P$) | Clinically relevant differences between groups at 18 months$^a$ | Clinically meaningful changes within group from baseline to 6 months$^b$ | Clinically meaningful changes within group from baseline to 18 months$^b$ |
|------------|-----------|-----------|----------|----------|-----------|------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|
| **Fatigue** |           |           |          |          |           |                                                      |                                                                |                                                                |                                                                |                                                                 |                                                                 |
| HI         | 27 (20)   | 38 (25)   | 25 (20)  | 25 (21)  |           | -2 Trivial                                           |                                                                |                                                                |                                                                | -1 Trivial                                                      | -1 Trivial                                                      |
| LMI        | 30 (23)   | 37 (25)   | 25 (19)  | 25 (19)  |           | -4 Trivial*                                          |                                                                |                                                                |                                                                | -5 Small*                                                       | -5 Small*                                                       |
| UC         | 23 (17)   | 34 (23)   | 31 (24)  | 26 (22)  |           | + 9 Small*                                           |                                                                |                                                                |                                                                | + 4 Trivial                                                     | + 4 Trivial                                                     |
| HI vs LMI  |           | 1.0 (-2.3 to 4.2) | 0.56     | + 1 Trivial | 2.3 (-1.2 to 5.7) | 0.20 | + 2 Trivial | 2.3 (-1.2 to 5.7) | 0.20 | + 2 Trivial | -1 Trivial | -1 Trivial | -5 Small* | -5 Small* | + 4 Trivial | + 4 Trivial |
| HI vs UC   |           | -11 (-18 to -4.5) | < 0.01  | -11 Small* | -5.6 (-12 to 1.1) | 0.10 | -6 Small* | -5.6 (-12 to 1.1) | 0.10 | -6 Small* | + 4 Trivial | + 4 Trivial |
| LMI vs UC  |           | -12 (-19 to -5.6) | < 0.01  | -12 Small* | -7.9 (-14 to -1.2) | 0.02 | -8 Small* | -7.9 (-14 to -1.2) | 0.02 | -8 Small* | + 4 Trivial | + 4 Trivial |
| **Nausea and vomiting** |            |           |          |          |          |                                                      |                                                                |                                                                |                                                                |                                                                 |                                                                 |
| HI         | 3.5 (9.3) | 7.1 (13)  | 2.9 (9.2) | 1.9 (6.3) |           | -1 Trivial                                           |                                                                |                                                                |                                                                | -2 Small*                                                       | -2 Small*                                                       |
| LMI        | 3.1 (8.1) | 6.5 (12)  | 2.3 (7.8) | 2.5 (8.3) |           | -1 Trivial                                           |                                                                |                                                                |                                                                | + 1 Trivial                                                     | + 1 Trivial                                                     |
| UC         | 3.0 (7.4) | 6.5 (13)  | 1.8 (7.6) | 4.1 (18)  |           | -1 Trivial                                           |                                                                |                                                                |                                                                | + 1 Trivial                                                     | + 1 Trivial                                                     |
| HI vs LMI  |           | 0.3 (-1.3 to 1.9) | 0.74     | 0 Trivial | -1.0 (-2.6 to 0.6) | 0.21 | -1 Trivial | -1.0 (-2.6 to 0.6) | 0.21 | -1 Trivial | -1 Trivial | -1 Trivial | -1 Trivial | -1 Trivial | -2 Trivial | -2 Trivial |
| HI vs UC   |           | 1.3 (-0.9 to 3.4) | 0.26     | + 1 Trivial | -3.0 (-7.7 to 1.8) | 0.22 | -3 Trivial | -3.0 (-7.7 to 1.8) | 0.22 | -3 Trivial | 0 Trivial | 0 Trivial | 0 Trivial | 0 Trivial | 1 Trivial | 1 Trivial |
| LMI vs UC  |           | 1.0 (-1.1 to 3.1) | 0.36     | -2 Trivial | -1.9 (-6.7 to 2.8) | 0.42 | + 1 Trivial | -1.9 (-6.7 to 2.8) | 0.42 | + 1 Trivial | 0 Trivial | 0 Trivial | 0 Trivial | 0 Trivial | 1 Trivial | 1 Trivial |
| **Pain**   |           |           |          |          |          |                                                      |                                                                |                                                                |                                                                |                                                                 |                                                                 |
| HI         | 19 (22)   | 24 (27)   | 20 (24)  | 21 (24)  |           | + 1 Trivial                                           |                                                                |                                                                |                                                                | + 3 Trivial                                                     | + 3 Trivial                                                     |
| LMI        | 22 (24)   | 23 (26)   | 17 (21)  | 19 (23)  |           | -5 Small*                                           |                                                                |                                                                |                                                                | + 2 Trivial                                                     | + 2 Trivial                                                     |
| UC         | 17 (19)   | 17 (23)   | 17 (22)  | 19 (25)  |           | + 2 Trivial                                          |                                                                |                                                                |                                                                | + 4 Trivial                                                     | + 4 Trivial                                                     |
| HI vs LMI  |           | 4.7 (0.9 to 8.5) | 0.02     | + 5 Trivial* | 3.8 (-0.6 to 8.2) | 0.09 | + 4 Trivial | 3.8 (-0.6 to 8.2) | 0.09 | + 4 Trivial | -2 Trivial | -2 Trivial | -2 Trivial | -2 Trivial | -4 Trivial | -4 Trivial |
| HI vs UC   |           | -0.2 (-6.7 to 6.3) | 0.95     | 0 Trivial | -1.3 (-8.9 to 6.4) | 0.74 | -1 Trivial | -1.3 (-8.9 to 6.4) | 0.74 | -1 Trivial | -2 Trivial | -2 Trivial | -2 Trivial | -2 Trivial | -4 Trivial | -4 Trivial |
| LMI vs UC  |           | -4.9 (-11 to 1.6) | 0.14     | -5 Trivial | -5.1 (-13 to 2.6) | 0.19 | -5 Trivial | -5.1 (-13 to 2.6) | 0.19 | -5 Trivial | -4 Trivial | -4 Trivial | -4 Trivial | -4 Trivial | -8 Trivial | -8 Trivial |
| Table 2 (continued) | Mean (SD) | Baseline | 3 months | 6 months | 18 months | Between groups differences at 6 months (95% CI and P) | Clinically relevant differences between groups at 6 months<sup>a</sup> | Clinically meaningful changes within group from baseline to 6 months<sup>b</sup> | Between groups differences at 18 months (95% CI and P) | Clinically relevant differences between groups at 18 months<sup>a</sup> | Clinically meaningful changes within group from baseline to 18 months<sup>b</sup> |
|---------------------|-----------|----------|----------|----------|-----------|------------------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|
| Dyspnoea            |           |          |          |          |           |                                                 |                                                 |                                                 |                                                 |                                                 |                                                 |
| HI                  | 10 (19)   | 20 (28)  | 8.5 (19) | 10 (20)  | -1 Trivial | -3.0 (-6.4 to 0.4) 0.08 -3 Trivial | 0.1 (-3.7 to 3.8) 0.97 0 Trivial | 6 Small                                             |                                                 | +1 Trivial                                             |
| LMI                 | 8.8 (17)  | 19 (26)  | 9.8 (18) | 9.4 (20) | +2 Trivial* | -9.2 (-16 to -2.7) 0.01 -9 Small* | -3.7 (-11 to 3.5) 0.32 -4 Small | +2 Trivial                                             |                                                 | +2 Trivial                                             |
| UC                  | 4.9 (14)  | 12 (22)  | 13 (24)  | 11 (24)  | +9 Small* | -6.2 (-13 to 0.3) 0.06 -6 Small | -3.8 (-11 to 3.4) 0.30 -4 Small | +6 Small                                             |                                                 | 6 Small                                             |
|                    |           |          |          |          |           |                                                 |                                                 |                                                 |                                                 |                                                 |                                                 |
| HI vs LMI           |           |          |          |          |           | -3.0 (-6.4 to 0.4) 0.08 -3 Trivial | 0.1 (-3.7 to 3.8) 0.97 0 Trivial | 6 Small                                             |                                                 | 6 Small                                             |
| HI vs UC            |           |          |          |          |           | -9.2 (-16 to -2.7) 0.01 -9 Small* | -3.7 (-11 to 3.5) 0.32 -4 Small | +2 Trivial                                             |                                                 | +2 Trivial                                             |
| LMI vs UC           |           |          |          |          |           | -6.2 (-13 to 0.3) 0.06 -6 Small | -3.8 (-11 to 3.4) 0.30 -4 Small | +6 Small                                             |                                                 | 6 Small                                             |
| Insomnia            |           |          |          |          |           |                                                 |                                                 |                                                 |                                                 |                                                 |                                                 |
| HI                  | 30 (30)   | 36 (30)  | 31 (30)  | 28 (29)  | +2 Trivial | 1.4 (-3.5 to 6.3) 0.58 +1 Trivial | 1.3 (-3.8 to 6.4) 0.61 +1 Trivial | -1 Trivial                                             |                                                 | -2 Trivial                                             |
| LMI                 | 31 (30)   | 32 (32)  | 30 (30)  | 27 (28)  | +2 Trivial | -0.1 (-8.6 to 8.4) 0.98 0 Trivial | -5.2 (-15 to 4.2) 0.28 -5 Small | +2 Trivial                                             |                                                 | +5 Trivial                                             |
| UC                  | 29 (30)   | 33 (31)  | 31 (31)  | 31 (31)  | +5 Trivial | -1.5 (-9.9 to 6.9) 0.73 -1 Trivial | -6.5 (-16 to 3.0) 0.18 -6 Small | +5 Trivial                                             |                                                 | +5 Trivial                                             |
|                    |           |          |          |          |           |                                                 |                                                 |                                                 |                                                 |                                                 |                                                 |
| HI vs LMI           |           |          |          |          |           | 1.4 (-3.5 to 6.3) 0.58 +1 Trivial | 1.3 (-3.8 to 6.4) 0.61 +1 Trivial | -1 Trivial                                             |                                                 | -2 Trivial                                             |
| HI vs UC            |           |          |          |          |           | -0.1 (-8.6 to 8.4) 0.98 0 Trivial | -5.2 (-15 to 4.2) 0.28 -5 Small | +2 Trivial                                             |                                                 | +5 Trivial                                             |
| LMI vs UC           |           |          |          |          |           | -1.5 (-9.9 to 6.9) 0.73 -1 Trivial | -6.5 (-16 to 3.0) 0.18 -6 Small | +5 Trivial                                             |                                                 | +5 Trivial                                             |
| Appetite loss       |           |          |          |          |           |                                                 |                                                 |                                                 |                                                 |                                                 |                                                 |
| HI                  | 9.5 (20)  | 12 (22)  | 4.7 (14) | 6.3 (18) | -5 Small* | 0.3 (-2.2 to 2.9) 0.79 0 Trivial | 1.7 (-1.7 to 5.1) 0.33 2 Trivial | -3 Small*                                             |                                                 | -3 Small*                                             |
| LMI                 | 10 (19)   | 13 (24)  | 4.3 (12) | 4.7 (16) | -5 Small* | -2.5 (-6.9 to 2.4) 0.34 -2 Trivial | -3.9 (-10 to 2.2) 0.21 -4 Trivial | -5 Small*                                             |                                                 | -5 Small*                                             |
| UC                  | 6.4 (19)  | 9.5 (20) | 4.8 (17) | 6.1 (22) | -2 Trivial | -2.6 (-7.1 to 1.9) 0.26 -3 Trivial | -5.6 (-12 to 0.5) 0.07 -6 Small | +1 Trivial                                             |                                                 | +1 Trivial                                             |
|                    |           |          |          |          |           |                                                 |                                                 |                                                 |                                                 |                                                 |                                                 |
|                           | Mean (SD) | Baseline | 3 months | 6 months | 18 months | Clinically relevant differences at 6 months (95% CI and \( P \)) | Clinically meaningful changes within group from baseline to 6 months\(^a\) | Clinically relevant differences at 18 months (95% CI and \( P \)) | Clinically meaningful changes within group from baseline to 18 months\(^b\) |
|--------------------------|---------|---------|---------|---------|---------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|
| **Constipation**         |         |         |         |         |         |                                                               |                                                               |                                                               |                                                               |
| HI                      | 5.5 (15) | 13 (23) | 6.4 (16) | 6.6 (16) |         | +1 Trivial                                                   | +1 Trivial                                                   |                                                               |                                                               |
| LMI                     | 6.8 (17) | 13 (22) | 9.3 (20) | 8.9 (19) |         | +2 Trivial                                                   | +2 Trivial                                                   |                                                               |                                                               |
| UC                      | 6.4 (16) | 9.5 (23) | 7.7 (18) | 10 (23)  |         | +2 Trivial                                                   | +6 Small                                                    |                                                               |                                                               |
| Hi vs LMI                |         |         |         |         |         | -1.8 (-4.8 to 1.3)                                            | 0.26 -2 Trivial                                              | -0.6 (-3.8 to 2.5)                                            | 0.69 -1 Trivial                                               |
| Hi vs UC                 |         |         |         |         |         | -2.1 (-6.6 to 2.4)                                            | 0.35 -2 Trivial                                              | -5.0 (-12 to 1.8)                                             | 0.15 -5 Trivial                                               |
| LMI vs UC                |         |         |         |         |         | -0.4 (-4.9 to 4.1)                                            | 0.86 0 Trivial                                              | -4.4 (-11 to 2.4)                                             | 0.20 -4 Trivial                                               |
| **Diarrhoea**            |         |         |         |         |         |                                                               |                                                               |                                                               |                                                               |
| HI                      | 8.4 (19) | 14 (23) | 7.1 (18) | 7.0 (18) |         | -1 Trivial                                                   | 1 Trivial                                                   | -1 Trivial                                                   | -1 Trivial                                                   |
| LMI                     | 8.4 (19) | 15 (24) | 9.2 (19) | 7.5 (19) |         | +1 Trivial                                                   | +1 Trivial                                                   |                                                               |                                                               |
| UC                      | 7.6 (19) | 14 (21) | 11 (22) | 8.8 (22) |         | +3 Trivial                                                   | +1 Trivial                                                   |                                                               |                                                               |
| Hi vs LMI                |         |         |         |         |         | -1.9 (-5.4 to 1.6)                                            | 0.28 -2 Trivial                                              | -0.6 (-4.0 to 2.7)                                            | 0.71 -1 Trivial                                               |
| Hi vs UC                 |         |         |         |         |         | -4.2 (-9.7 to 1.3)                                            | 0.13 -2 Trivial                                              | -5.2 (-12 to 1.5)                                             | 0.13 -5 Trivial                                               |
| LMI vs UC                |         |         |         |         |         | -2.3 (-7.8 to 3.3)                                            | 0.42 0 Trivial                                              | -4.5 (-11 to 2.1)                                             | 0.18 -4 Trivial                                               |
| **Financial difficulties** |       |         |         |         |         |                                                               |                                                               |                                                               |                                                               |
| HI                      | 9.8 (21) | 9.9 (21) | 9.4 (22) | 7.4 (18) |         | -1 Trivial                                                   | -2 Trivial                                                  | -1 Trivial                                                   | -1 Trivial                                                   |
| LMI                     | 12.1 (24) | 11 (23) | 9.8 (19) | 5.9 (16) |         | -2 Trivial                                                   | -0 Trivial                                                  | -5 Small*                                                    | -4 Small                                                    |
| UC                      | 9.8 (21) | 8.5 (21) | 7.9 (22) | 3.4 (12) |         | +1 Trivial                                                   | +0 Trivial                                                  | 3.1 (-0.3 to 6.6)                                             | 0.07 +3 Trivial                                               |
| Hi vs LMI                |         |         |         |         |         | 0.8 (-2.1 to 3.7)                                             | 0.58 +1 Trivial                                              | 2.6 (-1.1 to 6.2)                                             | 0.16 +3 Trivial                                               |
| Hi vs UC                 |         |         |         |         |         | -1.2 (-6.4 to 4.2)                                            | 0.68 -1 Trivial                                              | -0.6 (-4.1 to 3.0)                                            | 0.75 -1 Trivial                                               |
| LMI vs UC                |         |         |         |         |         | -1.9 (-7.2 to 3.3)                                            | 0.47 -2 Trivial                                              | 2.6 (-1.1 to 6.2)                                             | 0.16 +3 Trivial                                               |

Results of EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30; are presented as means±S.D. (range). A high score for the global health status/QoL and functional scale represents a high level of the global health status/QoL and functioning. A high score for a symptom scale/item represents a high level of symptoms/problems. \( a \): Interpreted as clinically relevant as defined by Cocks et al. 2011 b: Interpreted as clinically meaningful as defined by Cocks et al. 2012: Trivial = no/unlikely difference, S = small change of subtle clinical relevance, M = medium change of likely clinical relevance, NA = no available guidelines. Differences are adjusted according to baseline measurement of each outcome, and age, education, hospital, cancer diagnosis and treatment. * = indicates significant differences. Bold font indicates clinically meaningful. HI = high intensity exercise; LMI = low-to-moderate intensity exercise, UC = usual care.
LMI groups scored worse for sexual functioning (mean difference $= -5.5$; 95% CI, $-10$ to $1.1$ and mean difference $= -6.3$; 95% CI, $-11$ to $-1.9$), and there was more hair loss in the LMI group (mean difference $= 8.7$; 95% CI, $0.2$ to $17$) compared with UC. In participants with prostate cancer, both the HI and LMI groups reported better sexual functioning (mean difference $= 21.8$; 95% CI, $5.4$ to $38$ and mean difference $= 25.6$; 95% CI, $9.7$ to $42$) and the HI group reported more bowel symptoms (mean difference $= 5.8$; 95% CI, $1.0$ to $11$) compared with UC. The sample of participants with colorectal cancer was too small to perform any diagnosis-specific analysis (Supplement material).

**Discussion**

This large study demonstrates novel and clinically important results on HRQoL, directly comparing HI vs LMI exercise for 6 months during oncological treatment and up to 1 year after the intervention was completed. We found no significant differences on HRQoL between the exercise intensities over time, except for participants randomised to HI exercise who reported significant higher pain compared with LMI exercise directly after the intervention was completed. However, this difference was not clinically relevant. Small to medium beneficial clinical changes within both exercise intensities were persistent up to 1 year after the intervention was completed. Thus, our findings indicate that to improve or prevent a decline in HRQoL, combining resistance and endurance training of either LMI or HI is recommended. In addition, the present study confirmed that supervised exercise during treatment could be beneficial for many aspects of HRQoL compared with UC (although not randomised, discussed in detail below) and also up to 18 months after commencement of treatment.

Our results show that exercise, irrespective of intensity level, could have a beneficial impact on HRQoL up to 1 year after the end of the exercise intervention. This confirms and adds to the findings of a meta-analysis covering 66 studies with different methodologies and cancer patient cohorts, showing a beneficial effect but only immediately after the end of interventions [14]. In addition, our study showed that improvements persisted, regardless of the exercise intensity, up to 1 year after the intervention. Due to methodological differences in the included studies, the meta-analysis could only be conducted for overall QoL, global health status/QoL and physical function, whereas in our study, we were able to investigate all aspects of HRQoL.

In the shorter term, directly after the intervention was completed, the only significant, but not clinically relevant difference between the exercise intensity groups in our study, was higher symptoms of pain with HI exercise compared to LMI. Since other studies have shown that high intensity exercise is beneficial in reducing pain compared to usual care [17, 32], it remains unclear to what degree the higher pain in our study is attributed to HI exercise. Thus, more research is needed to explore this finding. Our results of no significant differences between the exercise intensities of other HRQoL outcomes confirm a smaller randomised study by van Waart et al. [17]. However, van Waart et al. did not directly compare exercise intensities of an exercise programme comprising both endurance and resistance training as we did. Another exercise trial by Kampshoff et al. also reported no significant differences on HRQoL between HI and LMI exercise directly after the exercise intervention [18]. However, Kampshoff et al. conducted an exercise intervention after completion of chemotherapy, and it is proven to be more beneficial to start exercise during chemotherapy.

In the longer term, 1 year after completion of the exercise intervention, no significant difference between the exercise intensities was found in our study, confirming the results of van Waart et al. [17]. However, they only followed up for 6 months after completion of the exercise interventions. In contrast to our results, Kampshoff et al. found larger effects of high intensity exercise on HRQoL compared to low-to-moderate exercise [19].

Our study also reports novel information about clinically meaningful changes of HRQoL within both the HI and LMI groups that persisted 1 year after the intervention. These are important results for cancer survivors, since they are at risk of developing long-term symptoms [6]. Our results are surprisingly positive, as we would expect these outcomes to further deteriorate when the intervention has ended. The intervention in our study lasted for as long as 6 months, which is an appropriate period of time to establish physically active behaviour [33]. A majority of the participants maintained physical activity 1 year after the intervention ended [34]. Thus, a reasonable explanation for the maintained improvements might be that the exercise intervention introduced participants to the habit of exercise, which they continued with. The adherence to the exercise programme in Phys-Can RCT had an acceptable rate of $\geq 50\%$ [35]; however, we did not control for whether the participants continued to perform the exercise programme on their own.

Our results confirm previous findings of exercise trials [8, 36], with short-term effects of improved global health status/QoL [14], functioning [14, 17, 32] and reduced fatigue [17, 32] from exercise during oncological treatment compared to usual care. These findings strengthen the hypothesis that supervision in groups can improve aspects of HRQoL [14, 37, 38]. Thus, this study provides important confirmatory findings to support the exercise recommendations [15]. Improvements in HRQoL can be expected when combining supervised resistance and endurance training for a longer period of time.
Our results also confirm that exercise during treatment can have beneficial effects on HRQoL compared to usual care in the longer term. Similar results regarding better emotional functioning and reduced symptoms of fatigue were found by Mijwel et al. at the 12-month follow-up after commencement of treatment of a programme of high intensity aerobic interval training combined with moderate intensity aerobic training [39]. However, comparison with other studies is difficult due to differences in intervention characteristics and follow-up times. Thus, more studies are needed to confirm the long-term effects of exercise.

Participants with breast cancer reported more hair loss and lower sexual functioning with both exercise intensities compared with UC. It is unlikely that these results are due to the exercise. The UC group received less chemotherapy than those in the RCT, and this could explain the lower mean values of side effects of the chemotherapy [40].

The strengths of our study were a long-term follow-up 1 year after completion of the exercise intervention and the use of a self-reported HRQoL outcome from a large multicentre RCT comparing LMI to HI exercise, with limited loss to follow-up. The exercise intervention followed a thoroughly standardised protocol, ensuring that the intervention was carried out in a very rigorous manner in which both the exercise delivered, and the exercise volume and intensity were monitored.

The main limitation of our study was that, for comparison, we used a smaller non-randomised UC group included before the RCT, making the groups not directly comparable. However, the main aim of the Phys-Can was to compare different levels of exercise intensity; thus, we considered it unethical to design an RCT randomising participants to usual care since there are strong evidence that exercise have a positive effect on fatigue and HRQoL [8]. In the present study, the measured characteristics of the participants in UC were almost as similar as in the RCT, except that a smaller proportion in the UC group received chemotherapy, and analyses were adjusted accordingly. To try to avoid bias, we used a mixed model approach with adjustment for auxiliary variables to handle missing data. Another limitation was that our results were based on exploratory analysis with multiple endpoints of the subscales of HRQoL, and the statistical power analysis was based on the main outcome physical fatigue in the RCT. Thus, the internal validity of our findings may be limited. Moreover, our results may not be generalisable to all patients with breast, colorectal and prostate cancer receiving (neo)adjuvant oncological treatment. Those who consented to participation were a relatively healthy group compared with the general cancer population. Only 29% of the eligible patients chose to participate in the RCT, and this sample might have been biased, as they were probably motivated to exercise. Also, participants with breast cancer were over-represented.

In conclusion, patients with breast, colorectal and prostate cancer can exercise at either intensity level according to their personal preferences and will still benefit from short-term and long-term improvements in HRQoL. The key clinical message is to recommend patients to exercise according to their personal condition. Exercise on low-to-moderate intensity is sufficient to achieve beneficial health effects and to improve symptoms of the oncological treatment. Future studies are needed to confirm our results in broader clinical populations.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s00520-022-07016-3.

Author contributions Conception and design: Karin Nordin, Sussanne Börjeson, Birgitta Johansson, Anna-Karin Ax.
Provision of study materials or patients: Karin Nordin, Sussanne Börjeson, Birgitta Johansson, Anna-Karin Ax.
Collection and assembly of data: Anna-Karin Ax.
Data analysis and interpretation: All authors.
Manuscript writing: All authors.
Final approval of manuscript: All authors.

Funding Open access funding provided by Linköping University. This work was supported by grants from the Swedish Cancer Society; the Swedish Research Council; the Region Östergötland, Sweden and The Oncology Department Foundations Research Fund in Linköping, Sweden.

Data availability The data that support the findings of this study are available from the corresponding author upon request.

Declarations

Ethics approval The study was approved by the Swedish Ethical Review Authority in Uppsala (Dnr 2014/249). The study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

Consent to participate Written informed consent was obtained from all participants.

Consent for publication N/A.

Competing interests The authors no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
References

1. Ferlay J, Colombo M, Soerjomataram I, Mathers C, Parkin DM, Pfeiffer RM, Znaor A, Bray F (2019) Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 144(8):1941–1953. https://doi.org/10.1002/ijc.31937

2. Fong DY, Ho JW, Hui BP, Lee AM, Macfarlane DJ, Leung SS, Cerin E, Chan WY, Leung IP, Lam SH, Taylor AJ, Cheng KK (2012) Physical activity for cancer survivors: meta-analysis of randomised controlled trials. BMJ (Clinical research ed) 344:e70. https://doi.org/10.1136/bmj.e70

3. LeMasters T, Madhavan S, Sambamoorthi U, Kurian S (2013) A population-based study comparing HRQoL, among breast, prostate, and colorectal cancer survivors to propensity score matched controls, by cancer type, and gender. Psychooncology 22(10):2270–2282. https://doi.org/10.1002/pon.3288

4. Stout NL, Silver JK, Raj VS, Rowland J, Gerber L, Cheville A, Ness KK, Radomska M, Nitkin R, Stubblefield MD, Morris GS, Acevedo A, Brandon Z, Braemvan B, Cunningham S, Gilchrist L, Jones L, Padgett L, Wolf T, Winters-Stone K, Campbell G, Hendricks J, Perkin K, Chan L (2016) Toward a national initiative for cancer rehabilitation: recommendations from a subject matter expert group. Arch Phys Med Rehabil 97(11):2006–2015. https://doi.org/10.1016/j.apmr.2016.05.002

5. Bower JE (2014) Cancer-related fatigue—mechanisms, risk factors, and treatments. Nat Rev Clin Oncol 11(10):597–609. https://doi.org/10.1038/nrclinonc.2014.127

6. Wu HS, Harden JK (2015) Symptom burden and quality of life in survivorship: a review of the literature. Cancer Nurs 38(1):E29–54. https://doi.org/10.1097/NCC.0000000000000135

7. Shapiro CL (2018) Cancer Survivorship. N Engl J Med 379(25):2438–2450. https://doi.org/10.1056/NEJMra1712520

8. Mishra SI, Scherer RW, Snyder C, Geigle PM, Berlanstein DR, Topaloglu O (2012) Exercise interventions on health-related quality of life for people with cancer during active treatment. Cochrane Database Syst Rev (8):Cd008465. https://doi.org/10.1002/14651358.CD008465.pub2

9. Gerritsen JK, Vincent AJ (2016) Exercise improves quality of life in patients with cancer: a systematic review and meta-analysis of randomised controlled trials. Br J Sports Med 50(13):796–803. https://doi.org/10.1136/bjsports-2015-094778

10. Stout NL, Baima J, Swisher AK, Winters-Stone KM, Welsh J (2017) A systematic review of exercise system reviews in the cancer literature (2005–2017). Pm r 9(9s2):S347–s384. https://doi.org/10.1016/j.pmr.2017.07.074

11. Scott K, Posmontier B (2017) Exercise interventions to reduce cancer-related fatigue and improve health-related quality of life in cancer patients. Holist Nurs Pract 31(2):66–79. https://doi.org/10.1097/HNP.0000000000000194

12. Segal R, Zwaal C, Green E, Tomasone JR, Lohlaw A, Petrella T (2017) Exercise for people with cancer: a clinical practice guideline. Curr Oncol (Toronto, Ont) 24(1):40–46. https://doi.org/10.1037/co.24.3.3747

13. Buffart LM, Kalter J, Sweegers MG, Courneya KS, Newton RU, Aaronson NK, Jacobsen PB, May AM, Galvao DA, Chinapaw MJ, Steindorf K, Irwin ML, Stuiver MM, Hayes S, Griffith KA, Lucia AL, Lindman H, Johansson S, Velikova G, Raatstad T, Buffart LM, Vreugdenhil A, Twisk JW, Bosmans JE, Buffart MM, Chinapaw MJ, van den Bergh M, Sonke GS, Aaronson NK (2015) Effect of low-intensity physical activity and moderate-to high-intensity physical exercise during adjuvant chemotherapy on physical fitness, fatigue, and chemotherapy completion rates: results of the PACES randomised clinical trial. J Clin Oncol 33(17):1918–1927. https://doi.org/10.1200/jco.2014.59.1081

14. Campbell KL, Winters-Stone KM, Wiskemann J, May AM, Schwartz AL, Courneya KS, Huisman M, Nieschalk S, Perna FM, Schmitz KH (2019) Exercise guidelines for cancer survivors: consensus statement from international multidisciplinary roundtable. Med Sci Sports Exerc 51(11):2375–2390. https://doi.org/10.1249/mss.0000000000002116

15. Vreugdenhil A, Ho JW, Hui BP, Lee AM, Macfarlane DJ, Courneya KS, Zucker DS, Matthews CE, Ligibel JA, Gerber LH, Morris GS, Patel AV, Hue TF, De Langhe S, Selby P (2019) Exercise interventions to reduce cancer-related fatigue and improve health-related quality of life and physical function in patients with cancer: an individual patient data meta-analysis of 34 RCTs. Cancer Treat Rev 52:91–104. https://doi.org/10.1016/j.ctrv.2016.11.010

16. Sweegers MG, Altenburg TM, Chinapaw MJ, Kalter J, Verdonck-de Leeuw IM, Courneya KS, Newton RU, Aaronson NK, Jacobsen PB, Buffart LM (2018) Which exercise prescriptions improve quality of life and physical function in patients with cancer during and following treatment? A systematic review and meta-analysis of randomised controlled trials. Br J Sports Med 52(8):505–513. https://doi.org/10.1136/bjsports-2017-097891

17. van Wijst T, Stuiver MM, van Herten WH, Geleijn J, Kief er JM, Buffart LM, de Maaker-Berkhof M, Boven E, Schrama J, Geenen MM, Meerum Terwogt JM, van Bochove A, Lustig V, van den Heijligenberg SM, Smorenburg CH, Hellendoorn-van Vreeswijk JA, Sonke GS, Aaronson NK (2015) Effect of low-intensity physical activity and moderate-to high-intensity physical exercise during adjuvant chemotherapy on physical fitness, fatigue, and chemotherapy completion rates: results of the PACES randomized clinical trial. J Clin Oncol 33(17):1918–1927. https://doi.org/10.1200/jco.2014.59.1081

18. Kampshoff CS, Chinapaw MJ, Brug J, Twisk JW, Schep G, Nijziel MR, van Mechelen W, Buffart LM (2015) Randomized controlled trial of the effects of high intensity and low-to moderate intensity exercise on physical fitness and fatigue in cancer survivors: results of the Resistance and Endurance exercise After ChemoTherapy (REACT) study. BMC Med 13:275. https://doi.org/10.1186/s12916-015-0513-2

19. Kampshoff CS, van Dongen JM, van Mechelen W, Schep G, Vreugdenhil A, Twisk JW, Bosmans JE, Brug J, Chinapaw MJM, Buffart LM (2018) Long-term effectivity and cost-effectivity of high versus low-to moderate intensity resistance and endurance exercise interventions among cancer survivors. J Cancer Surviv 12(3):417–429. https://doi.org/10.1007/s11766-018-0681-0

20. Demmelmaier I, Brooke HL, Henriksson A, Mazzoni AS, Bjørke ACH, Igelström H, Ax AK, Sjövall K, Hellbom M, Ping gel R, Lindman H, Johansson S, Velikova G, Raatstad T, Buffart LM, Åsenlöf P, Aaronson NK, Gillemelius B, Nygren P, Johansson B, Börjeson S, Berntsen S, Nordin K (2021) Does exercise intensity matter for fatigue during (neo-)adjuvant cancer treatment? The Phys-Can randomised clinical trial. Scand J Med Sci Sports. https://doi.org/10.1111/sms.13930

21. Berntsen S, Aaronson NK, Buffart L, Börjeson S, Demmelmaier I, Hellbom M, Hofman J, Igelström H, Johansson B, Pin gel R, Lindman H, Johansson S, Velikova G, Raatstad T, Buffart LM, Åsenlöf P, Aaronson NK, Gillemelius B, Nygren P, Johans son B, Börjeson S, Berntsen S, Nordin K (2021) Does exercise intensity matter for fatigue during (neo-)adjuvant cancer treatment? The Phys-Can randomised clinical trial. Scand J Med Sci Sports. https://doi.org/10.1111/sms.13930

22. Sems EM, Garssen B, Bonke B, De Haes JC (1995) The Multi-dimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res 39(3):315–325

23. Henriksson A, Johansson B, Radu C, Berntsen S, Igelström H, Nordin K (2021) Is it safe to exercise during oncological
treatment? A study of adverse events during endurance and resistance training – data from the Phys-Can study. Acta Oncol 60(1):96–105. https://doi.org/10.1080/0284186X.2020.1851046
24. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtnier H, Fleishman SB, de Haes JC et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365–376
25. Giesing JM, Kieffer JM, Fayers PM, Groenvold M, Petersen MA, Scott NW, Sprangers MA, Velikova G, Aaronson NK (2016) Replication and validation of higher order models demonstrated that a summary score for the EORTC QLQ-C30 is robust. J Clin Epidemiol 69:79–88. https://doi.org/10.1016/j.jclinepi.2015.08.007
26. Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A (2001) EORTC QLQ-C30 Scoring Manual. European Organisation for Research and Treatment of Cancer, Denmark, Europe
27. Sprangers MA, Groenvold M, Arraras JI, Franklin J, te Velde A, Muller M, Franzini L, Williams A, de Haes HC, Hopwood P, Cull A, Aaronson NK (1996) The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. J Clin Oncol 14(10):2756–2768. https://doi.org/10.1200/jco.1996.14.10.2756
28. Whistance RN, Conroy T, Chie W, Costantini A, Sezer O, Koller M, Johnson CD, Pilkinson SA, Arraras J, Ben-Josef E, Pullyblank AM, Fayers P, Blazey JM (2009) Clinical and psychometric validation of the EORTC QLQ-CR29 questionnaire module to assess health-related quality of life in patients with colorectal cancer. Eur J Cancer 45(17):3017–3026. https://doi.org/10.1016/j.ejca.2009.08.014
29. van Andel G, Bottomley A, Efficace F, Coens C, D’Haese S, Fossá SD, Guerif S, Kynaston H, Gontero P, Thalmann G, Akdas A, Aaronson NK (2008) An international field study of the EORTC QLQ-PR25: A questionnaire for assessing the health-related quality of life of patients with prostate cancer. Eur J Cancer 44(16):2418–2424. https://doi.org/10.1016/j.ejca.2008.07.030
30. Cocks K, King MT, Velikova G, de Castro G Jr, Martyn St-James M, Fayers PM, Brown JM (2012) Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. Eur J Cancer 48(11):1713–1721. https://doi.org/10.1016/j.ejca.2012.02.059
31. Cocks K, King MT, Velikova G, Martyn St-James M, Fayers PM, Brown JM (2011) Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. J Clin Oncol 29(1):89–96. https://doi.org/10.1200/jco.2010.28.0107
32. Mijwel S, Backman M, Bolam KA, Jervaeus A, Sundberg CJ, Margolin S, Browall M, Rundqvist H, Wengstrom Y (2018) Adding high-intensity interval training to conventional training modalities: optimizing health-related outcomes during chemotherapy for breast cancer: the OptiTrain randomized controlled trial. Breast Cancer Res Treat 168(1):79–93. https://doi.org/10.1007/s10549-017-4571-3
33. Demark-Wahnefried W, Peterson B, McBride C, Lipkus I, Clipp E (2000) Current health behaviors and readiness to pursue lifestyle changes among men and women diagnosed with early stage prostate and breast carcinomas. Cancer 88(3):674–684
34. Mazzoni AS, Brooke HL, Berntsen S, Nordin K, Demmelmaier I (2021) Effect of self-regulatory behaviour change techniques and predictors of physical activity maintenance in cancer survivors: a 12-month follow-up of the Phys-Can RCT. BMC Cancer 21(1):1272. https://doi.org/10.1186/s12885-021-08996-x
35. Mazzoni AS, Brooke HL, Berntsen S, Nordin K, Demmelmaier I (2020) Exercise Adherence and Effect of Self-Regulatory Behavior Change Techniques in Patients Undergoing Curative Cancer Treatment: Secondary Analysis from the Phys-Can Randomized Controlled Trial. Integr Cancer Ther 19:1534735420946834. https://doi.org/10.1177/1534735420946834
36. Furmaniak AC (2016) Exercise for women receiving adjuvant therapy for breast cancer. Cochrane Database Syst Rev (9):Cd005001. https://doi.org/10.1002/14651858.CD005001.pub3
37. Ax AK, Johansson B, Carlsson M, Nordin K, Borjeson S (2020) Exercise: A positive feature on functioning in daily life during cancer treatment - Experiences from the Phys-Can study. Eur J Oncol Nurs 44:101713. https://doi.org/10.1016/j.ejcon.2019.101713
38. Sweegers MG, Buffart LM, van Veldhuizen WM, Geleijn E, Verheul HMW, Brug J, Chinapaw MJM, Altenburg TM (2019) How does a supervised exercise program improve quality of life in patients with cancer? a concept mapping study examining patients’ perspectives. Oncologist 24(6):e374–e383. https://doi.org/10.1634/theoncologist.2017-0613
39. Mijwel S, Jervaeus A, Bolam KA, Norrbom J, Bergh J, Rundqvist H, Wengstrom Y (2019) High-intensity exercise during chemotherapy induces beneficial effects 12 months into breast cancer survivorship. J Cancer Surviv. https://doi.org/10.1007/s11764-019-00747-z
40. Fobair P, Stewart SL, Chang S, D’Onofrio C, Banks PJ, Bloom JR (2006) Body image and sexual problems in young women with breast cancer. Psychooncology 15(7):579–594. https://doi.org/10.1002/pon.991

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.